216 related articles for article (PubMed ID: 22414856)
21. Altered behavioral phenotypes in soluble epoxide hydrolase knockout mice: effects of traumatic brain injury.
Strauss KI; Gruzdev A; Zeldin DC
Prostaglandins Other Lipid Mediat; 2013; 104-105():18-24. PubMed ID: 22922090
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney.
Luo J; Hu S; Fu M; Luo L; Li Y; Li W; Cai Y; Dong R; Yang Y; Tu L; Xu X
J Biol Chem; 2021; 296():100667. PubMed ID: 33864813
[TBL] [Abstract][Full Text] [Related]
23. 14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease.
Chen W; Wang M; Zhu M; Xiong W; Qin X; Zhu X
J Neurosci; 2020 Oct; 40(42):8188-8203. PubMed ID: 32973044
[TBL] [Abstract][Full Text] [Related]
24. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice.
Deng Y; Edin ML; Theken KN; Schuck RN; Flake GP; Kannon MA; DeGraff LM; Lih FB; Foley J; Bradbury JA; Graves JP; Tomer KB; Falck JR; Zeldin DC; Lee CR
FASEB J; 2011 Feb; 25(2):703-13. PubMed ID: 21059750
[TBL] [Abstract][Full Text] [Related]
25. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.
Koeners MP; Wesseling S; Ulu A; Sepúlveda RL; Morisseau C; Braam B; Hammock BD; Joles JA
Am J Physiol Endocrinol Metab; 2011 Apr; 300(4):E691-8. PubMed ID: 21266668
[TBL] [Abstract][Full Text] [Related]
26. Soluble epoxide hydrolase: a new target for cardioprotection.
Gross GJ; Nithipatikom K
Curr Opin Investig Drugs; 2009 Mar; 10(3):253-8. PubMed ID: 19333883
[TBL] [Abstract][Full Text] [Related]
27. Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase.
Luria A; Morisseau C; Tsai HJ; Yang J; Inceoglu B; De Taeye B; Watkins SM; Wiest MM; German JB; Hammock BD
Am J Physiol Endocrinol Metab; 2009 Aug; 297(2):E375-83. PubMed ID: 19458064
[TBL] [Abstract][Full Text] [Related]
28. The liver X receptor agonist TO901317 protects mice against cisplatin-induced kidney injury.
Yang M; Wang R; Sun J; Yu K; Chen B; Xu L; Zhao B; Wang H
Exp Biol Med (Maywood); 2015 Dec; 240(12):1717-27. PubMed ID: 26062799
[TBL] [Abstract][Full Text] [Related]
29. Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3β signaling pathway.
Liang Y; Jing Z; Deng H; Li Z; Zhuang Z; Wang S; Wang Y
Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):70-5. PubMed ID: 25986738
[TBL] [Abstract][Full Text] [Related]
30. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.
Manhiani M; Quigley JE; Knight SF; Tasoobshirazi S; Moore T; Brands MW; Hammock BD; Imig JD
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F740-8. PubMed ID: 19553349
[TBL] [Abstract][Full Text] [Related]
31. Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice.
Zhang W; Yang AL; Liao J; Li H; Dong H; Chung YT; Bai H; Matkowskyj KA; Hammock BD; Yang GY
Dig Dis Sci; 2012 Oct; 57(10):2580-91. PubMed ID: 22588244
[TBL] [Abstract][Full Text] [Related]
32. Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency.
Zhang W; Liao J; Li H; Dong H; Bai H; Yang A; Hammock BD; Yang GY
Mol Carcinog; 2013 Sep; 52(9):726-38. PubMed ID: 22517541
[TBL] [Abstract][Full Text] [Related]
33. Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis.
Li L; Li N; Pang W; Zhang X; Hammock BD; Ai D; Zhu Y
PLoS One; 2014; 9(4):e94092. PubMed ID: 24718617
[TBL] [Abstract][Full Text] [Related]
34. New insights into the protection of growth hormone in cisplatin-induced nephrotoxicity: The impact of IGF-1 on the Keap1-Nrf2/HO-1 signaling.
Mahran YF
Life Sci; 2020 Jul; 253():117581. PubMed ID: 32209424
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
Kim J; Long KE; Tang K; Padanilam BJ
Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
[TBL] [Abstract][Full Text] [Related]
36. Soluble Epoxide Hydrolase Pharmacological Inhibition Decreases Alveolar Bone Loss by Modulating Host Inflammatory Response, RANK-Related Signaling, Endoplasmic Reticulum Stress, and Apoptosis.
Trindade-da-Silva CA; Bettaieb A; Napimoga MH; Lee KSS; Inceoglu B; Ueira-Vieira C; Bruun D; Goswami SK; Haj FG; Hammock BD
J Pharmacol Exp Ther; 2017 Jun; 361(3):408-416. PubMed ID: 28356494
[TBL] [Abstract][Full Text] [Related]
37. Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia.
Edin ML; Hamedani BG; Gruzdev A; Graves JP; Lih FB; Arbes SJ; Singh R; Orjuela Leon AC; Bradbury JA; DeGraff LM; Hoopes SL; Arand M; Zeldin DC
J Biol Chem; 2018 Mar; 293(9):3281-3292. PubMed ID: 29298899
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.
Koerner IP; Jacks R; DeBarber AE; Koop D; Mao P; Grant DF; Alkayed NJ
J Neurosci; 2007 Apr; 27(17):4642-9. PubMed ID: 17460077
[TBL] [Abstract][Full Text] [Related]
39. Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model.
Chen L; Fan C; Zhang Y; Bakri M; Dong H; Morisseau C; Maddipati KR; Luo P; Wang CY; Hammock BD; Wang MH
Prostaglandins Other Lipid Mediat; 2013; 104-105():42-8. PubMed ID: 23247129
[TBL] [Abstract][Full Text] [Related]
40. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels.
Olearczyk JJ; Field MB; Kim IH; Morisseau C; Hammock BD; Imig JD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1307-14. PubMed ID: 16772540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
